Relative Bioavailability of BI 1291583 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
Latest Information Update: 25 Jul 2022
At a glance
- Drugs BI 1291583 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 24 Apr 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2019 Status changed from not yet recruiting to recruiting.